flumazenil

The pharmacologic profile of flumazenil is unaltered in the presence of benzodiazepine agonists and the kinetics profiles of those benzodiazepines are unaltered by flumazenil. 7,10

Flumanazil 2010

Isolated in 1981, flumazenil is an imidazobenzodiazepine capable of blocking the centrally mediated effects of benzodiazepines at the receptor level. 4 Its utility may parallel that of naloxone in opiate toxicity; however, controversy over its use in the emergency department persists. 5

Flumanazil 2010

An imidazobenzodiazepine derivative, flumazenil antagonizes the actions of benzodiazepines on the CNS.

Flumanazil 2010

The duration and degree of reversal are related to the plasma concentration of the benzodiazepine as well as the dose of flumazenil. 7,10

Flumanazil 2010

O'Sullivan reported a significant increase in the GCS scores (in relation to their baseline) for the subgroups receiving flumazenil with confirmed benzodiazepine overdoses and mixed overdoses with benzodiazepines.

Flumanazil 2010

Hojer J, Baehrendtz S, Matell G, Gustaffson L. Diagnostic utility of flumazenil in coma with suspected poisoning: a double blind, randomized controlled study.

Flumanazil 2010

Klotz U, Kanto J. Pharmacokinetics and clinical use of flumazenil (Ro 15-1788).

Flumanazil 2010

Adverse effects most frequently associated with flumazenil alone were limited to dizziness, injection site pain, increased sweating, headache and abnormal or blurred vision.

Flumanazil 2010

After IV administration, flumazenil plasma concentrations follow a two compartment model with an initial distribution half-life ofseven to 15 minutes and a terminal half-life of 41 to 79 minutes.

Flumanazil 2010

Moreover in polydrug ingestions unresponsive to flumazenil no seizure activity or arrhythmias occurred.

Flumanazil 2010